Erasca (ERAS) was higher in Thursday trading as market attention returned to the company’s ERAS-0015 program and a recently disclosed clinical trial collaboration and supply agreement with Tango Therapeutics to study ERAS-0015 in combination with PRMT5 inhibitor vopimetostat. The agreement frames a new development path in MTAP-deleted settings where combination approaches are a major investor focus in RAS-pathway oncology. (biospace.com)

The planned Phase 1/2 trial is designed to evaluate ERAS-0015 plus vopimetostat in MTAP-deleted pancreatic cancer and MTAP-deleted RAS-mutant non-small cell lung cancer, with Tango sponsoring the study and Erasca supplying ERAS-0015 at no cost. Investors often treat combination access—especially with a mechanistically complementary agent—as a way to expand both clinical relevance and potential partnering interest for early-stage RAS programs. (biospace.com)

Erasca has already highlighted early clinical activity for ERAS-0015 during dose escalation and has guided to initial Phase 1 monotherapy data in the first half of 2026, creating a near-term window where positioning and incremental updates can drive outsized moves. This backdrop can amplify sensitivity to any program-validation signal, including new combination-trial plans that align with the company’s stated 2026 milestones. (erasca.com)

Key swing factors include timing and details of trial activation for the ERAS-0015/vopimetostat study (sites, dose-escalation cadence, and initial safety/PK observations), as well as any interim commentary tied to ERAS-0015’s planned 2026 monotherapy readout. Separately, traders may monitor insider and filing-related headlines that can influence short-term flows around a volatile biotech tape. (biospace.com)